8-K filing — ACADIA PHARMACEUTICALS INC (ACAD)
Filed: 2026-09-24 AccNo: 0001193125-26-401157 Size: 190 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Acadia Drug Misses Primary Goal in Alzheimer’s Related Psychosis
Acadia Pharmaceuticals reports Phase 2 remlifanserin trial results for Alzheimer’s psychosis and plans to move into Phase 3.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Citigroup Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $33
Citigroup analyst Yigal Nochomovitz maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers the price target from $40 to $33.
Acadia Pharma shares are trading lower after the company announced remlifanserin narrowly missed the primary endpoint in its Phase 2 RADIANT study for Alzheimer's disease psychosis.